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Abstract
Background: The aim of  this study was to investigate the association of  25(OH)D levels with biochemical, anthropometric, 
and metabolic data obtained from normal and obese people.
Methods: This study was carried out on 90 individuals between the ages of  18 to 63 that had various body mass indexes. 
Blood samples and anthropometric measurements were taken.
Results: Waist circumferences, fat mass, LDL cholesterol levels, HDL cholesterol levels, 25(OH)D levels, and triglyceride 
levels were significantly different according to the body mass index groups of  the participants (p<0.05). When compared to 
the normal body mass index group, both other groups (overweight and obese) had higher waist circumferences, triglyceride 
levels, LDL cholesterol levels, fasting insulin levels, HOMA-IR ratios, parathyroid hormone levels, and fat mass, and had 
lower 25(OH)D levels (p<0.05). The overweight group participants had higher 25(OH)D levels than the obese group, and 
had lower waist circumferences, fat mass, fasting insulin level, HOMA-IR ratios, and HbA1C and PTH levels than those in 
the obese group (p<0.05).
Conclusion: In conclusion, the mean level of  25(OH)D is very low in overweight and obese individuals and low serum 
25(OH)D levels appear to be associated with obesity, visceral obesity, hypertriglyceridemia, insulin resistance, and metabolic 
syndrome in obese patients.
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Introduction
25(OH)D deficiency is an important public health 
problem in both developed and developing countries, 
with a reported worldwide prevalence of  30–80% in 
children and adults1-3. The role of  25(OH)D in bone 
mineralisation is well-documented. However, numer-
ous recent studies have reported a link between 25(OH)
D deficiency and several chronic disorders, such as type 
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1 diabetes mellitus, systemic lupus erythematosus, mul-
tiple sclerosis, cardiovascular disease, and several malig-
nancies4-6.
 
Positive associations between 25(OH)D deficiency and 
the prevalence of  obesity have been shown. Recent 
studies in the adult population suggested that adequate 
serum 25(OH)D levels could be connected with in-
creased adipocyte activity and oxidation of  fat, as well 
as the potential for improving insulin sensitivity, which 
can lead to weight loss7,8. The synthesis and processing 
of  25(OH)D confirmed that obese patients have lower 
basal 25(OH)D and higher serum parathyroid hormone 
concentrations than do nonobese people9-11. Several 
studies have shown that obese individuals tend to have 
lower serum concentrations of  vitamin D3 and 25(OH)
D3 than those with normal weights
9-12. For example, in 
one study, whole-body irradiation produced an increase 
in serum vitamin D3 levels in obese individuals [body 
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mass index (BMI) 30 kg/m2] that was 57% lower than 
that in age-matched, normal weight controls (BMI 25)13.
 
Since there is an inverse relationship between 25(OH)
D levels, the degree of  obesity14, and central adiposity15, 
it has been difficult to distinguish the independent ef-
fects of  obesity and 25(OH)D on metabolic syndrome. 
Furthermore, it is not known whether the association 
between 25(OH)D deficiency and the metabolic syn-
drome is still present at very high degrees of  obesity, 
in which the possible effect of  25(OH)D status on the 
metabolic syndrome could be ameliorated or even com-
pletely overcome by the predominant effect of  obesi-
ty16.
 
Several mechanisms have been proposed to explain the 
low 25(OH)D levels in obese people and include the 
sequestration of  25(OH)D by fat tissues17, as well as 
body size18. On the other hand, abnormal fasting serum 
or plasma lipid levels are the most prominent symp-
toms resulting from obesity19, and the effect of  25(OH)
D supplementation on lipid profiles remains controver-
sial20.
 
Studies showed that in Turkey, 25(OH)D deficiency is 
an important problem. There have been few studies 
about obesity and 25(OH)D levels in the Turkish pop-
ulation21,22. The aim of  this study was to investigate the 
association of  25(OH)D levels and certain biochemical, 
antropometric, and metabolic data in normal and obese 
people.
 
Methods
Study population
This study was performed with the participation of  90 
individuals between the ages of  18 and 63 with vari-
ous BMIs that were admitted to the Endocrinology de-
partment of  the Başkent University Ankara hospital’s 
Ümitköy polyclinic from June to November 2013. They 
were healthy and thus did not have any health prob-
lems at the time of  admission. People who were using 
any kind of  medicines, vitamins, or minerals were not 
included in this study. Pregnant or lactating women, as 
well as people with a pre-diagnosed diseases or those 
diagnosed with a disease during the study period, were 
not excluded.
Clinical and anthropometric characteristics
Height, weight, waist and hip circumferences were 
measured from 08:00 to 10:00 hours after a 12 h fast. 
Height was measured using a stadiometer accurate to 
±0.5 cm, and weight was obtained with participants 
wearing light clothing and no shoes using a calibrat-
ed scale, accurate to ±0.1 kg (Filizola S.A., São Paulo, 
SP, Brazil). The BMI was calculated using the stand-
ard equation (kilograms per meters squared). The waist 
circumference was measured with participants in the 
standing position, midway between the lower margin 
of  the last rib and the iliac crest, at mid exhalation. The 
hip circumference was measured at the widest point of  
the hip/buttocks area with the measuring tape parallel 
to the floor. The waist-to-hip ratio was determined by 
dividing waist circumference by hip circumference. An-
thropometric measurements were taken twice, and the 
mean values were used in all analyses. Systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) were 
measured twice in the sitting position, with 15 min be-
tween the measurements, using standard sphygmoma-
nometers of  appropriate width, after a rest period for 
30 min.
 
Biochemical analysis 
The percentage of  body fat was estimated by electrical 
bioimpedance using a Jawon IOI 353 body fat analyser 
(Biodynamics Corp., Seattle, WA, USA). We stratified 
adiposity as global adiposity (excessive adipose tissue, 
independent of  site) and abdominal adiposity. BMI and 
percentage of  body fat were used as global adiposity 
parameters. The waist circumference and waist-to-hip 
ratio were used to evaluate abdominal adiposity. Blood 
samples were collected after a 12 h fasting period. Bio-
chemical evaluation included glucose, total cholesterol, 
high-density lipoprotein cholesterol, low-density lipo-
protein cholesterol, triacylglycerols, calcium, phosfor, 
HbA1C, parathyroid hormone (PTH), and 25(OH)D. 
Fasting plasma glucose, total cholesterol, HDL-choles-
terol, LDL-cholesterol, TG, HbA1C, and calcium levels 
were measured using original kits and an Abbott-Aer-
oset autoanalyser (Architect C-8000, Chicago, Illinois, 
USA). Parathyroid hormone and fasting plasma insulin 
levels were measured using original kits using an Perfect 
Plus 400 autoanalyser (Mindray, UK). Insulin resistance 
was estimated from fasting serum measurements using 
the homeostasis model assessment-insulin resistance 
(HOMA-IR) [insulin (μU/mL) X glucose (mg/dL) ÷ 
425]. Metabolic syndrome was diagnosed according to 
NCEPATP III23. Thus, a participant had MS if  he or 
she had three or more of  the following: (i) abdominal 
obesity: waist circumference >102 cm in men and >88 
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cm in women; (ii) plasma triglycerides: ≥150 mg/dL; 
(iii) plasma HDL cholesterol: <40 mg/dL in men and 
<50 mg/dL in women; (iv) SBP: ≥130 mmHg, DBP: 
≥85 mmHg, or the use of  antihypertensive medicine; 
(v) plasma glucose: ≥110 mg/dL or the use of  antidia-
betic medicine/insulin.
 
Statistical analysis
Data are reported as mean ±SD for continuous vari-
ables and as numbers or a percentage for categorical 
variables. Clinical and biochemical characteristics were 
compared using the Student’s t test or the chi-square 
test when the variables were continuous or categorical, 
respectively. The Pearson correlation test was used to 
evaluate associations between serum 25(OH)D and 
components of  anthropometric and metabolic syn-
drome. Statistical analyses were performed using SPSS 
software, version 16.0 (SPSS Inc., Chicago, IL, USA).
  
Results
Waist circumferences, fat mass, and LDL cholesterol, 
HDL cholesterol, 25(OH)D, and triglyceride levels were 
significantly different according to the BMI groups of  
the participants (p<0.05; Table 1). When compared to 
the normal BMI group, both other groups (overweight 
and obese) had lower waist circumference, triglycer-
ide levels, LDL cholesterol levels, fasting insulin levels, 
HOMA-IR ratios, parathyroid hormone levels, and fat 
mass, and had higher 25(OH)D levels (p<0.05). The 
overweight group had higher 25(OH)D levels than 
obese group, and had lower waist circumferences, fat 
masses, fasting insulin levels, HOMA-IR ratios, and 
HbA1C and PTH levels than the obese group (p<0.05).
Table 1. Changes in biochemical and anthropometric indices between BMI classifications  
 
Variables   
Normal 
(n=30) 
Overweight 
(n=30) 
Obese 
(n=30) p 
 Mean        SD  Mean     SD  Mean        SD   
Age (year) 31.8 6.9 36.5 10.0 36.1 8.7 a, b, c p<0.05 
BMI (kg/m2) 22.1 2.1 26.4 1.3 33.1 3.2 a, b, c p<0.05 
WC (cm) 78.6 7.5 88.9 6.7 103.6 10.7 a, b, c p<0.05 
DBP 72.3 7.3 72.0 9.0 82.5 7.4 b, c p<0.05 
SBP 109.3 8.3 108.3 11.8 124.8 12.1 b, c p<0.05 
Fat mass (kg) 15.1 3.8 21.4 5.8 34.9 6.6 a, b, c p<0.05 
Fat mass (%) 22.8 5.8 28.8 5.6 33.8 5.4 a, b, c p<0.05 
Fasting glucose (mg/dL) 90.2 8.1 93.6 8.0 96.4 9.9 b p<0.05 
TC (mg/dL) 172.7 29.4 183.5 37.6 196.4 40.3 b p<0.05 
LDL-C (mg/dL) 106.3 24.0 125.8 33.0 133.5 35.6 a, b p<0.05 
HDL-C (mg/dL) 52.9 12.3 44.6 13.3 44.2 8.8 a, b p<0.05 
TG (mg/dL) 90.2 44.0 142.5 61.9 127.0 65.9 a, b p<0.05 
Fasting insulin (μU/ mL) 7.0 2.9 8.1 3.0 12.8 3.9 b, c p<0.05 
HOMA-IR ratio 1.6 0.7 1.9 0.7 3.1 1.1 b, c p<0.05 
HbA1C (%) 5.2 0.5 5.3 0.5 5.7 0.7 b, c p<0.05 
25(OH)D (μg/L) 27.5 8.3 21.3 5.8 16.2 4.4 a, c p<0.05 
Blood Ca (mg/dL) 9.5 0.4 9.3 0.3 9.3 0.3 b p<0.05 
PTH (pg/mL) 40.1 16.8 42.5 15.0 52.8 23.0 b, c p<0.05 
 
BMI, body mass index;WC, waist circumference; BP, blood pressure; HDL-C, high density lipoprotein-
cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; Ca, calcium; and PTH, parathyroid 
hormone. 
a significant diffrences between normal weight and overweight (p<0.05). 
b significant diffrences between normal weight and obese (p<0.05). 
c significant diffrences between overweight and obese (p<0.05). 
 
African Health Sciences Vol 15 Issue 4, December 20151163     
Table 2 lists the clinical and biochemical characteristics 
of  the participants separated according to 25(OH) D 
levels: <20 ng/mL (deficiency) and ≥20 ng/mL (suffi-
ciency). The mean TG and HDL-C level was significant-
ly different in the sufficiency group than in the deficien-
cy group (p<0.05). The deficiency group had slightly 
higher mean blood PTH, TC, LDL-C, TG, and fasting 
glucose levels when compared to those in the sufficien-
cy group, although this trend was not statistically signif-
icant (p>0.05). The mean BMI, WC, fat mass, fasting 
insulin levels, HOMA-IR ratios, and HbA1C, DPB, and 
SBP levels were significantly lower in the sufficiency 
group than in the deficiency group (p<0.05). 
Table 2. Characteristics of participants based on serum 25(OH)D concentrations 
 
  
  
Suficient (n=44) 
≥20μg/L 
Deficiency (n=46) 
<20μg/L 
p 
Metabolic syndrome 4 (9.0%) 12 (26.1%) 0.032 * 
  Mean S.D. Mean S.D.   
BMI (kg/m2) 25.7 4.5 28.7 5.2 0.005 * 
WC (cm) 86.6 11.1 94.0 14.3 0.008 * 
Fat Mass (kg) 20.3 6.7 27.2 10.8 0.000 * 
TC (mg/dL) 178.1 34.7 190.2 38.6 0.131 
LDL-C (mg/dL) 117.0 31.2 126.5 34.3 0.174 
HDL-C (mg/dL) 48.6 11.2 43.1 10.6 0.017 
TG (mg/dL) 107.1 60.4 141.9 66.9 0.012 * 
Fasting glucose (mg/dL) 92.9 9.2 93.9 8.8 0.615 
Fasting insulin (μU/ mL 8.0 3.3 10.6 4.5 0.003 * 
HOMA-IR ratio 1.9 0.8 2.5 1.2 0.006 * 
HbA1C (%) 5.3 0.5 5.6 0.7 0.011 * 
Diatolic BP (mmHg) 73.3 8.8 77.8 9.2 0.019 * 
Sistolic BP (mmHg) 110.5 10.8 117.7 14.3 0.008 * 
25(OH)D (μg/L) 27.7 6.4 15.9 3.6 0.000 * 
Blood Ca (mg/dL) 9.4 0.4 9.3 0.3 0.449 
PTH (pg/mL) 43.6 18.0 46.6 20.4 0.457 
 
BMI, body mass index; WC, waist circumference; BP, blood pressure; HDL-C, high density 
lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; Ca, calcium; 
and PTH, parathyroid hormone. 
* significantly different between the two groups (p<0.05). 
  
 
The Pearson's correlation coefficients (r) for selected 
baseline variables are shown in Table 3. At baseline, 
25(OH)D levels correlated inversely with BMIs (r = 
−0.469; p = 0.000), waist circumferences (r = −0.432; 
P = 0.000), fat masses (r = −0.419; p = 0.004), fasting 
insulin levels (r = −0.432; p = 0.000), and HOMA-IR (r 
= −0.341; p = 0.001).  
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Table 3. Relationship between serum 25(OH)D levles and anthropometric  
and metabolic risk factors 
 
  Total (n=90) Female (n=45) Male (n=45) 
 VIT D Ca PTH VIT D Ca PTH VIT D Ca PTH 
BMI 
(kg/m2) 
-
0.469** 
-0.234* 0.320** -
0.519** 
-0.244 0.266 -
0.417** 
-0.242 0.373* 
WC (cm) -
0.432** 
-0.105 0.195 -
0.532** 
-0.172 0.173 -
0.407** 
-0.192 0.232 
DBP 
(mmHg) 
-
0.293** 
-0.138 0.108 -0.342* -0.278 0.070 -0.215 0.026 0.156 
SBP 
(mmHg) 
-
0.311** 
-
0.280** 
0.162 -0.359* -
0.397** 
0.107 -0.235 -0.152 0.234 
TC 
(mg/dL) 
-0.172 0.008 -0.079 -0.089 0.098 -0.056 -0.274 -0.079 -0.102 
LDL-C 
(mg/dL) 
-0.183 -0.092 0.002 -0.096 0.009 0.086 -0.298* -0.244 -0.103 
HDL-C 
(mg/dL) 
0.144 0.248* -0.150 0.208 0.373* -0.191 0.105 0.298* -0.110 
TG 
(mg/dL) 
-0.129 0.023 0.025 -0.193 0.042 -0.040 -0.062 -0.066 0.066 
Fat mass 
(kg) 
-
0.419** 
-0.258 0.333* -
0.523** 
-0.242 0.225 -
0.419** 
-0.258 0.333* 
Fasting 
glucose 
(mg/dL) 
-0.173 -0.067 0.143 -0.163 -0.169 0.092 -0.176 -0.029 0.187 
Fasting 
insulin 
(μU/ mL) 
-
0.346** 
-0.090 0.303** -
0.466** 
-0.345* 0.342* -0.282 0.007 0.298* 
HOMA-
IR ratio 
-
0.341** 
-0.087 0.288** -
0.486** 
-0.369* 0.348* -0.287* -0.007 0.284* 
HbA1C 
(%) 
-0.261* -0.148 -0.115 -0.346* -0.213 -0.066 -0.130 -0.160 -0.205 
 
BMI, body mass index; WC, waist circumference; BP, blood pressure; HDL-C, high density lipoprotein-cholesterol; 
LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; Ca, calcium; and PTH, parathyroid hormone. 
* p<0.05 
** p<0.01 
  
Discussion
25(OH)D deficiency is increasingly being recognised 
worldwide2,24. There have been prevalence studies on 
25(OH)D deficiency and/or insufficiency in the Turk-
ish population25, and most have been performed on 
women, people in nursing homes, and the elderly26-28. 
Also, obesity leads to many health problems world-
wide. It is a major public health problem and the most 
common nutritional disorder29. It is related to a host 
of  health problems. In particular, abdominal obesity is 
associated with some serious problems, such as type 2 
diabetes, cardiovascular and cerebrovascular diseases, 
hypertension, digestive disorders, and cancer30. The 
highest mean prevalence of  obesity is 32.05% and 
was reported in the TEKHARF (men, 21.1%; women, 
43.0%). The highest obesity frequency in women was 
also reported in this study (43.0%). The mean obesi-
ty in the TURDEP was 22.3% (men, 12.9%; women, 
29.9%)31. Obesity is usually correlated with a higher 
prevalence of  hypovitaminosis or a lower circulating 
African Health Sciences Vol 15 Issue 4, December 20151165     
25(OH)D level32,33. However, in the present study, the 
prevalence of  25(OH)D deficiency was higher in the 
overweight and obese groups than in the normal weight 
group. Over the past few decades, research has shown 
positive and negative associations between weight loss 
and maintenance with increased 25(OH)D and calcium 
intake (particularly with dairy products) in adults34-36. 
Additionally, studies have demonstrated links between 
a high BMI and decreased sun exposure, as well as de-
creased 25(OH)D levels37.
 
Previous studies have shown this association between 
25(OH)D deficiency and metabolic syndrome in wom-
en14 and in the general population15, and our present 
findings confirm these results also in overweight and 
obese people. Pittas et al. reported that the risk for 
developing type 2 diabetes was lower for those whose 
25(OH)D levels were higher38. On the other hand, in 
a study carried out in postmenopausal women, it has 
been reported that low 25(OH)D levels were not asso-
ciated with a risk of  developing diabetes39. In our study, 
the serum 25(OH)D deficieny was associated with 
high fasting insulin levels and hyperparathyroidism. In 
cross-sectional and epidemiological studies, the rela-
tionship of  25(OH)D deficiency with DM type I, meta-
bolic syndrome, obesity, cardiovascular diseases, hyper-
tension, and mortality, possibly due to the role of  this 
vitamin in insulin resistance, secretion, and inflammato-
ry processes, were reported40-43. It has also been shown 
that deficiencies in serum 25(OH)D levels decreases 
insulin secretion by reducing calcium absorption and, 
therefore, causing secondary hyperparathyroidism and 
increased peripheral insulin resistance44. 
The most promising study to date suggesting that 
25(OH)D alters diabetes risk is a post hoc analysis 
from an osteoporosis intervention study in which 314 
nondiabetic white adults were randomised to groups 
recieving either 700 IU of  the vitamins D3 and 500 
mg calcium citrate or placebos daily for 3 years. Treat-
ment with 25(OH)D and calcium citrate demonstrated 
attenuated increases in fasting glucose in participants 
with baseline impaired fasting glucose (IFG), but not 
in those with normal fasting glucose. Participants with 
IFG who received 25(OH)D and calcium also had re-
duced progression of  insulin resistance, as assessed by 
HOMA-IR45. Conversely, a Women’s Health Initiative 
(WHI) study reported that daily supplementation with 
400 IU of  vitamin D3 and 1000 mg of  calcium did not 
reduce risk of  developing diabetes over 7 years, when 
compared to placebo46. In the present study, we found 
a significant difference between 25(OH)D deficient in-
dividuals and those with normal 25(OH)D level regard-
ing HOMA-IR and HbA1c levels. This is in agreement 
with Chiu et al., who observed a positive relationship 
between 25(OH)D status and insulin sensitivity index 
in adults. In addition, they showed that 25(OH)D levels 
were negatively correlated with both first and second 
phase insulin responses during a hyperglycemic clamp 
and glucose levels during the oral glucose tolerance test. 
Therefore, they suggested that subjects with hypovi-
taminosis D not only displayed impaired β-cell func-
tion, causing impaired glucose homeostasis, but were 
also at increased risk of  developing insulin resistance 
and metabolic syndrome when compared with vitamin 
D sufficient subjects47. Also, previous studies showed 
that serum 25(OH) D levels were inversely correlated 
with HbA1c, independent of  body fat, implying higher 
ambient glucose concentrations in children with lower 
25(OH)D concentrations48,49.
Previous studies showed an inverse relationship be-
tween 25(OH)D levels and BMI14, as well as central ad-
iposity15, making it difficult to distinguish the separate 
contributions of  obesity and of  25(OH)D to the devel-
opment of  metabolic syndrome. Similarly, our findings 
indicated that  a low 25(OH)D level is associated with a 
high BMI and central obesity. In contrast, Botella-Car-
ratero et al.16 reported that patients with and without 
25(OH)D deficiency had similar BMIs and waist cir-
cumferences, so the differences in metabolic syndrome 
prevalence and lipid levels may indeed reflect a true as-
sociation between 25(OH)D status and the metabolic 
syndrome, irrespective of  adiposity.
 
Low serum 25(OH)D was associated with compo-
nents of  the metabolic syndrome, including abdom-
inal obesity, hypertension, hypertriglyceridemia, and 
higher HbA1C and lower high-density cholesterol50. In 
the present study, we found that low serum vitamin D 
levels related to high abdominal obesity, high body fat, 
hypertriglyceridemia, and lower high-density choles-
terol.  Two cross-sectional studies (NHANES III and 
NHANES 2003–2004) showed a significant inverse as-
sociation between serum 25(OH)D concentrations and 
metabolic syndrome15,51. 
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In the current study, PTH levels correlated positively 
with BMI, fat mass, HOMA-IR ratio and fasting insulin 
levels.  The association of  PTH with impaired glucose 
tolerance is part of  a newly proposed mechanism un-
derlying the development of  the metabolic syndrome51. 
Other studies have also suggested that individuals with 
hyperparathyroidism have an increased risk of  devel-
oping type 2 diabetes52. Serum parathyroid concen-
trations have an important role in the mechanism of  
insulin resistance. Lee et al. shown that vitamin D  lev-
els are negatively correlated with metabolic syndrome 
frequency independent of  serum parathyroid levels53. 
Hyperparathyriodism secondary to decrease in serum 
25(OH)D levels was thought to be the main mechanism 
causing insulin resistance54. In a study conducted with 
1017 morbid obese, Caucasian, male and female sub-
jects, parathormone levels were found to be the only 
predictor of  metabolic syndrome rather than vitamin 
D levels55.
 
Limitations
This study had some limitations. The main one being 
the cross-sectional nature of  this study, with no causali-
ty effect to report. The sunlight exposure and effect of  
25(OH)D supplementation on weight gain also need to 
be considered. 
 
Conclusion
The mean level of  25(OH)D is very low in overweight 
and obese indiviuals, and low serum 25(OH)D levels 
appear to be associated with obesity, visceral obesity, 
hypertriglyceridemia, insulin resistance, and metabolic 
syndrome in obese individuals. A broad-based effort to 
prevent 25(OH)D deficiency in Turkey should be un-
dertaken.
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